Introduction
The Transpara Breast AI system is transforming breast cancer screening by delivering unmatched diagnostic precision and reducing false negatives. Developed with cutting-edge artificial intelligence, Transpara assists radiologists in detecting cancers that might otherwise go…
Esophageal cancer is one of the most deadly cancers — so why doesn’t the healthcare industry have better tools to prevent the disease?
Lucid Diagnostics is on a mission to solve that problem. The company…
Continue Reading
Advancing precision in lung cancer diagnostics: Lunit’s collaboration with AstraZeneca aims to transform the speed and accuracy of detecting actionable mutations in NSCLC. (Courtesy of Lunit)
What You Should Know:
– Lunit, a provider of AI…
Continue Reading
What You Should Know:
– Lunit, a leading provider of AI-powered cancer diagnostics solutions, has announced a strategic alliance with VIDI Group, the largest private radiology and radiotherapy network in France.
– The partnership will expand…
Continue Reading
Value-based care (VBC) models (which I’ve previously discussed) focus on reducing cost and improving health outcomes for defined “episodes” of care, with the expected cost of these episodes determined based on health needs and…
Continue Reading
What You Should Know:
– Starget Pharma, an innovative startup specializing in precision cancer diagnostics and targeted radiotherapy, has secured $5.1M in funding from Cancer Focus, a fund established in collaboration with the renowned MD…
Continue Reading
Introduction
Artificial intelligence (AI) is transforming breast cancer detection by enhancing early diagnosis and alleviating radiologist workload, essential for improving patient outcomes and screening efficiency. A recent study, conducted by researchers from Norway and Denmark,…
What You Should Know:
– miRoncol, a medtech startup, has announced the completion of proof-of-concept studies for a groundbreaking multi-cancer early detection blood test.
– The test utilizes microRNA analysis and machine learning, two technologies recognized…
Continue Reading
Funding will Support Expanded Commercialization Efforts for PreciseBreast Risk Assessment
PreciseDx, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for new, morphology-driven disease analysis, today announced that it has raised $20.7 million in…
What You Should Know:
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a partnership with the Agostino Gemelli University Polyclinic Foundation IRCCS (“Policlinico Gemelli”) to establish an in-house liquid biopsy testing…
Continue Reading
